Primary Biliary Cholangitis Trial, By Invitation (NCT07631442)

Primary Biliary Cholangitis Trial, By Invitation NCT07631442 Sponsor: Stanford University Condition: Primary Biliary Cholangitis

Printed from Voxsanity (voxsanity.com.au) — NCT07631442 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Primary Biliary Cholangitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Primary Biliary Cholangitis (PBC), a liver condition, based on at least 2 of the following 3 things: abnormal liver blood test results (specifically certain enzyme levels), a positive result on certain autoimmune blood tests, or a liver biopsy that supports the diagnosis (confirm with trial site).
You are able to read, understand, and sign a consent form agreeing to take part.
You are able to fill in questionnaires on a digital device (such as a phone, tablet, or computer).
Your blood tests show raised levels of a liver enzyme called alkaline phosphatase.

Who may not be able to join:

You have an ongoing, uncontrolled long-term inflammatory condition (such as certain autoimmune or inflammatory diseases) that could affect your energy levels or sleep and may interfere with the trial results (confirm with trial site).
You currently have cancer that is being actively treated.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07631442

Sponsor: Stanford University

Phase: Not Applicable

Status: By Invitation

Condition: Primary Biliary Cholangitis

More information: https://clinicaltrials.gov/study/NCT07631442

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Primary Biliary Cholangitis (PBC), a liver condition, based on at least 2 of the following 3 things: abnormal liver blood test results (specifically certain enzyme levels), a positive result on certain autoimmune blood tests, or a liver biopsy that supports the diagnosis (confirm with trial site).
You are able to read, understand, and sign a consent form agreeing to take part.
You are able to fill in questionnaires on a digital device (such as a phone, tablet, or computer).
Your blood tests show raised levels of a liver enzyme called alkaline phosphatase.

Who may not be able to join:

You have an ongoing, uncontrolled long-term inflammatory condition (such as certain autoimmune or inflammatory diseases) that could affect your energy levels or sleep and may interfere with the trial results (confirm with trial site).
You currently have cancer that is being actively treated.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

By Invitation

Phase

Not Applicable

Sponsor

Stanford University

Registry

ClinicalTrials.gov

Start date

1 July 2026

Est. completion

1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Sleep scores to assess sleep quality will be measured in PBC patients using a wearable device; SpO2 (saturation of peripheral oxygen) levels to assess sleep quality; Total time in bed, to assess sleep quality; Total sleep, to assess sleep quality; Sleep stage time series (REM), to assess sleep quality; Sleep stage time series (deep), to assess sleep quality; Sleep stage time series (light), to assess sleep quality; Number of "get ups" during sleep, to assess sleep quality; Temperature deviation from baseline, to assess sleep quality; Heart rate; Respiratory rate; Calories burned during exercis...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov